Source link : https://newshealth.biz/health-news/fda-intensifies-crackdown-on-glp-1-compounding/
The FDA is proposing the removal of three GLP-1 drugs from the 503B bulks list of active ingredients that outsourcing facilities can use to make compounded medicines, the agency announced on Thursday. Following a review, the FDA found no clinical need for outsourcing facilities to compound semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, […]
The post FDA Intensifies Crackdown on GLP-1 Compounding first appeared on News Health.
—-
Author : News Health
Publish date : 2026-04-30 18:34:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8